Scandinavian Real Heart recruits new employee and establishes contact with Texas Heart Institute in Houston and with Cleveland Clinic.
After performing successful tests on version 11, Scandinavian Real Heart will shortly end the pre-clinical tests on sleeping animals, and start a new phase of pre-clinical survival tests. These tests will initially be performed in cooperation with the University Hospital in Linköping. Subsequently, tests will be performed at a certified laboratory in the United States. When we have reached a satisfactory result from the pre-clinical animal tests we will start the planning for clinical tests on humans.
Scandinavian Real Heart has established contact with Texas Heart Institute in Houston and with Cleveland Clinic. Texas Heart is the one clinic in the world with the most experience regarding pre-clinical tests of heart pumps. Cleveland Clinic has performed a large number of tests on calves the last couple of years and have substantial experience of the ethical handling of the test animals. The CEO and Chairman of the Company will visit the American clinics in the end of May. Texas Heart has already (on the basis of the information that we have supplied) declared that they are interested in discussing a future cooperation.
Scandinavian Real Heart has recruited Ina Pieper to the company. She will start in August. Ina has previously worked at the University of Swansea, where she has worked with heart pump related research for several years. She is one of few in the world with a PhD within the area of blood chemistry and the effects of heart pumps. Ina will now, after several years abroad, move back to Sweden to work in our project. This is an important and strategic recruitment regarding the the regulatory work with our heart pump.
The company follows the established development plan, and as previously communicated the company’s future capital needs need to be met for the continued work. At the coming Annual Meeting meeting, it will be proposed that the meeting gives the board authority to decide on, at one or several occacions, increasing the company’s share capital through a new issue. In connection with a new share issue, the Board shall also take reasonable account of the existing shareholders’ preferential rights. This proposal has already been communicated in the notice convening the Annual Meeting
For more information, please Contact:
Azad Najar, CEO
073-667 34 63
About Scandinavian Real Heart AB – Only approximately 5000 heart transplants are performed yearly in the world, and the supply of donor hearts is very limited. The need is great, and patients with heart failure die while waiting for a new heart. Scandinavian Real Heart is developing a heart pump (TAH) that mimics the body’s natural circulation, that will be possible to use as a temporary solution for patients waiting for a heart transplant.